Business
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
SAN DIEGO, February 24, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market LLC ("Nasdaq") formally notified the Company that REVB common stock will continue to be listed and traded on Nasdaq, as Revelation is in compliance with all requirements for continued listing.
About this update from Revelation Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":780,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/0ced18490f9cb8595b48ad13841249a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9fpPqDCfkwurIL9PPH6jHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0ced18490f9cb8595b48ad13841249a5","width":780,"height":315},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5xXq1uUTrx7De8XKXzo6mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE1NjA7aD02MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/0ced18490f9cb8595b48ad13841249a5","width":780,"height":315}},"lazy":false},{"type":"text","content":"SAN DIEGO, February 24, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market LLC ("Nasdaq") formally notified the Company that REVB common stock will continue to be listed and traded on Nasdaq, as Revelation is in compliance with all requirements for continued listing.","length":489,"tagName":"p"},{"type":"text","content":"On January 21, 2025, Revelation announced the commencement of its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The U.S. multi-site placebo-controlled study will enroll up to 40 patients in five cohorts of single escalating doses.","length":379,"tagName":"p"},{"type":"text","content":""We believe being listed on Nasdaq helps us maintain liquidity for our stockholders, gives us access to capital, and allows us to attract and retain the people we need to accomplish our research and drive our company forward in 2025 and beyond," said James Rolke, Chief Executive Officer, Revelation. "Our goal is to accelerate our growth and work to build a robust, high value company. We have recently commenced the Phase 1b PRIME (Preconditioning Immunostimulatory Evaluation) clinical study of escalating doses in the U.S., and we are excited to start dosing patients. We look forward to continued success as the study progresses...